Literature DB >> 30151020

Corrigendum to "Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial".

Chunhoo Cheon1, Jeong-Eun Yoo2, Hwa-Seung Yoo2, Chong-Kwan Cho2, Sohyeon Kang1, Mia Kim3, Bo-Hyoung Jang1, Yong-Cheol Shin1, Seong-Gyu Ko1.   

Abstract

[This corrects the article DOI: 10.1155/2017/8780325.].

Entities:  

Year:  2018        PMID: 30151020      PMCID: PMC6091375          DOI: 10.1155/2018/6162106

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


In the article titled “Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial” [1], there was an error in the conclusion of the Abstract where the text reading “Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy” should be corrected to “In the present study, Sipjeondaebo-tang did not show a significant effect on anorexia in patients with cancer. Further large-scale studies which compensate for the limitations of this study are needed to assess the efficacy”. This error in the reporting was brought to the attention of the journal by Professor Edzard Ernst, Emeritus Professor of Complementary Medicine, University of Exeter. The journal and the authors apologize for this misreporting of the conclusions.
  1 in total

1.  Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Chunhoo Cheon; Jeong-Eun Yoo; Hwa-Seung Yoo; Chong-Kwan Cho; Sohyeon Kang; Mia Kim; Bo-Hyoung Jang; Yong-Cheol Shin; Seong-Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-26       Impact factor: 2.629

  1 in total
  1 in total

Review 1.  Dropouts in randomized clinical trials of Korean medicine interventions: a systematic review and meta-analysis.

Authors:  Sae-Rom Jeon; Dongwoo Nam; Tae-Hun Kim
Journal:  Trials       Date:  2021-03-01       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.